parapsoriasis: one of a group of skin disorders that are characterized primarily by their resemblance to psoriasis (red, scaly lesions), rather than by their underlying etiology. Neoplasms can develop from parapsoriasis. For example, it can develop into cutaneous T-cell lymphoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
162 |
4. Check minimum number of eventsNone |
162 |
5. Include endpointsNone |
162 |
6. Filter based on genotype QC (FinnGen only) |
156 |
Control definitions (FinnGen only)
- Control exclude
- L12_PAPULOSQUAMOUS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified parapsoriasis
based on the number of shared cases.
Similar with more cases:
- Parapsoriasis
- Papulosquamous disorders
- Diseases of the skin and subcutaneous tissue
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1163 | 429 | 723 |
| Only index persons | 1003 | 377 | 626 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.01 | 0.02 |
| Only index persons | 0.02 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 58.23 | 55.63 | 59.80 |
| Only index persons | 58.11 | 55.18 | 59.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 156 | 62 | 94 |
| Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.04 |
| Median age at first event (years) | 56.38 | 56.97 | 55.99 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 162
- Matched controls
- 1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L41.9
ICD-10 Finland
Parapsoriasis, unspecified
+∞
110.4
93
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
19.9
83.3
86
87
L41.8
ICD-10 Finland
Other parapsoriasis
+∞
65.1
58
*
D07AB08
ATC
desonide; topical
10.0
42.0
61
92
L30.9
ICD-10 Finland
Dermatitis, unspecified
8.0
38.6
78
169
E0000UV, ,
ATC
8.2
35.3
122
438
E000001, ,
ATC
7.3
35.2
76
174
D07AC01
ATC
betamethasone; topical
7.3
34.1
112
380
E000002, ,
ATC
7.9
28.2
46
77
L40.0
ICD-10 Finland
Psoriasis vulgaris
64.2
23.9
27
5
L41.3
ICD-10 Finland
Small plaque parapsoriasis
+∞
23.5
22
*
C84.0
ICD-10 Finland
Mycosis fungoides
126.4
21.1
22
*
D07AC13
ATC
mometasone; topical
4.5
20.2
78
275
D07AD01
ATC
clobetasol; topical
4.7
15.8
45
123
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
81.9
13.8
15
*
69621
ICD-8 Finland
Psoriasis and similar disorders, Parapsoriasis guttata
+∞
13.7
13
*
D07AB02
ATC
hydrocortisone butyrate; topical
3.4
13.2
73
312
L41.4
ICD-10 Finland
Large plaque parapsoriasis
+∞
12.7
12
*
D07AA02
ATC
hydrocortisone; topical
4.2
12.3
39
114
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
3.3
11.1
56
223
D02AE01
ATC
carbamide; topical
5.4
9.6
20
41
Z2221
NOMESCO Finland
Medical doctor
2.9
9.3
61
278
D05BB02
ATC
acitretin; oral
39.1
9.1
11
*
D02AX
ATC
Other emollients and protectives
11.7
9.0
16
15
D07XC01
ATC
betamethasone; topical
3.9
8.5
28
83
D05AX52
ATC
calcipotriol, combinations; topical
8.9
8.3
17
21
E000006, ,
ATC
4.9
8.1
19
43
E000003, ,
ATC
8.5
8.1
17
22
E000007, ,
ATC
4.9
7.4
17
38
9700/3-C44.9
ICD-O-3
Mycosis fungoides of skin, NOS
+∞
7.3
7
*
D05AX02
ATC
calcipotriol; topical
12.8
7.2
12
10
XQ848
NOMESCO Finland
Dermatological photography
7.6
7.2
16
23
D07AC14
ATC
methylprednisolone aceponate; topical
6.7
6.7
16
26
69619
ICD-8 Finland
Psoriasis and similar disorders, Psoriasis alia sive NUD (vulgaris)
+∞
6.3
6
*
L41.1
ICD-10 Finland
Pityriasis lichenoides chronica
+∞
6.3
6
*
69623
ICD-8 Finland
Psoriasis and similar disorders, Parapsoriasis varioliformis
+∞
6.3
6
*
Z3231
NOMESCO Finland
Registered nurse
2.4
6.2
58
306
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
181
4.68
18.88
4.8
4.2
217.92
243.46
u/l
1.63
60
170
123
759
3.58
11.51
10.9
10.0
4.05
4.15
e9/l
0.18
117
665
10
5
21.17
7.22
1.4
1.6
—
—
—
0
0
20
58
3.79
6.24
1.5
2.0
2.92
3.14
g/l
0.44
20
51
19
54
3.85
6.09
1.5
2.0
0.57
0.56
g/l
0.01
19
48
20
61
3.60
5.80
1.5
1.9
3.55
3.57
g/l
0.03
20
54
20
61
3.60
5.80
1.5
1.9
—
—
—
0
0
20
61
3.60
5.80
1.5
1.9
6.76
7.50
g/l
1.20
20
54
17
53
3.47
4.77
1.5
2.0
37.28
36.28
g/l
0.26
17
46
78
512
2.01
4.53
2.4
2.2
75.20
76.91
nmol/l
0.21
73
444
45
259
2.02
3.66
4.5
3.2
2.46
2.46
mmol/l
0.10
39
227
5
5
10.26
3.00
2.8
1.4
581.80
1014.40
u/ml
—
5
5
20
94
2.29
2.68
4.0
4.2
90.82
88.13
ng/l
0.06
20
81
64
453
1.68
2.56
4.6
3.6
2.35
2.34
mmol/l
0.14
59
404
33
192
1.90
2.55
16.5
5.8
103.27
104.10
mmol/l
0.41
33
192
143
1269
2.08
2.39
22.2
15.3
75.88
76.36
ml/min/173m2
0.10
132
1034
41
263
1.75
2.32
3.9
3.6
383.56
297.14
ng/l
0.12
32
221
65
473
1.62
2.29
3.1
3.2
1442.49
1211.04
ng/l
0.32
56
404
75
567
1.60
2.25
2.5
1.9
94.13
93.82
pmol/l
0.02
47
290
57
404
1.63
2.22
4.0
3.2
0.19
0.67
e6/l
1.59
48
301
53
370
1.64
2.19
3.1
2.9
360.00
7604.14
umol/l
1.69
46
309
136
1200
1.83
2.12
5.2
4.5
1.91
2.04
mu/l
0.63
126
1068
68
511
1.57
2.05
4.1
3.3
—
—
—
0
0
19
99
2.04
2.00
1.7
1.7
—
—
—
0
0
112
952
1.57
1.88
4.4
3.7
15.34
14.89
pmol/l
1.07
104
845
21
117
1.91
1.85
3.8
3.2
4.89
4.41
kpa
0.50
21
111
85
684
1.51
1.82
10.5
6.6
1.22
1.21
mmol/l
1.27
73
577
151
1399
2.17
1.72
27.3
19.3
83.70
83.20
umol/l
0.06
151
1399
83
670
1.49
1.72
5.8
5.1
0.00
0.00
estimate
-0.00
17
135
84
682
1.48
1.68
4.0
3.7
0.00
0.00
estimate
-0.00
17
124
19
106
1.90
1.67
2.3
3.1
58.33
60.27
ml/min/173m2
—
6
44
34
228
1.62
1.61
3.5
2.0
29.01
29.32
s
0.16
34
221
34
228
1.62
1.61
3.3
2.9
2.25
2.05
e6/l
0.05
24
117
36
245
1.60
1.61
3.1
2.7
0.94
0.94
e6/l
0.00
25
132
8
33
2.50
1.56
1.0
1.2
—
—
—
0
0
82
670
1.45
1.55
4.0
3.7
0.00
0.01
estimate
0.50
17
144
12
58
2.15
1.53
1.3
1.3
—
—
—
0
0
143
1312
1.77
1.53
4.9
4.9
1.40
1.42
mmol/l
0.27
131
1194
23
141
1.74
1.52
4.7
4.1
5.81
5.70
kpa
0.26
23
136
14
73
2.00
1.49
3.4
3.0
0.51
0.67
%
1.29
14
73
6
22
2.79
1.45
8.2
4.2
—
—
—
0
0
143
1317
1.73
1.44
5.1
4.8
4.48
4.54
mmol/l
0.31
134
1212
7
29
2.48
1.41
2.7
1.5
—
—
—
0
0
7
29
2.48
1.41
2.7
1.5
—
—
—
0
0
7
29
2.48
1.41
1.1
1.1
—
—
—
0
0
32
219
1.57
1.40
1.3
1.3
20.89
39.73
iu/ml
—
9
73
37
262
1.53
1.40
1.4
1.2
0.93
1.20
u/ml
—
9
77
9
41
2.26
1.39
1.2
1.2
—
—
—
0
0
9
41
2.26
1.39
1.2
1.2
—
—
—
0
0
153
1448
2.02
1.39
34.9
23.2
40.52
40.28
%
0.18
146
1350
20
121
1.74
1.38
2.3
2.5
28.29
32.24
u/l
0.37
14
98
14
77
1.90
1.30
3.4
2.9
1.01
1.08
%
0.13
14
77
29
198
1.57
1.28
1.2
1.3
24.24
19.60
u/ml
0.12
14
67
142
1315
1.65
1.27
23.9
16.2
24.78
24.42
mg/l
0.05
119
1061
139
1281
1.60
1.27
4.4
4.3
1.27
1.29
mmol/l
0.10
127
1159
57
449
1.42
1.26
4.0
3.6
5.99
7.55
mg/mmol
0.20
40
273
6
25
2.45
1.25
3.2
3.8
57.17
59.12
%
—
6
25
138
1273
1.57
1.21
6.1
6.4
39.84
40.96
mmol/mol
0.93
132
1181
31
222
1.49
1.12
2.6
2.0
—
—
—
0
0
86
737
1.36
1.11
6.9
7.3
12.19
12.05
umol/l
0.05
80
695
7
32
2.24
1.09
1.4
1.3
—
—
—
0
0
144
1351
1.59
1.05
5.6
5.4
2.61
2.68
mmol/l
0.34
135
1232
24
165
1.53
1.04
2.8
1.8
—
—
—
0
0
24
167
1.51
0.99
2.7
1.9
—
—
—
0
0
6
27
2.27
0.94
1.2
1.4
—
—
—
0
0
38
294
1.38
0.92
2.7
1.7
1.12
1.44
mg/l
0.47
30
235
80
697
1.29
0.85
32.6
15.4
1.20
1.31
inr
0.58
22
208
79
699
1.25
0.71
2.3
2.5
—
—
—
0
0
10
62
1.65
0.66
1.0
1.0
—
—
—
0
0
137
1301
1.34
0.64
4.7
5.0
6.02
6.09
mmol/l
0.24
127
1181
46
386
1.27
0.64
3.3
3.2
0.52
0.78
ug/l
3.25
27
259
44
368
1.27
0.62
1.9
1.6
1.57
1.35
mmol/l
0.67
37
297
13
89
1.50
0.60
2.0
1.4
—
—
—
0
0
61
533
1.23
0.59
4.7
4.6
21.06
21.34
%
0.04
24
266
0
23
0.00
0.59
0.0
3.5
—
34.00
—
0
7
11
73
1.54
0.58
2.3
1.8
—
—
—
0
0
20
151
1.37
0.57
2.9
3.9
—
—
—
0
0
9
127
0.69
0.45
1.3
1.3
—
—
—
0
0
5
31
1.63
0.43
1.8
1.4
—
0.01
—
0
7
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
5
34
1.49
0.40
1.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.9
—
—
—
0
0
5
36
1.40
0.38
2.4
1.8
—
—
—
0
0
65
592
1.16
0.38
4.6
4.1
50.36
42.90
ng/l
0.15
45
451
72
664
1.15
0.35
6.1
5.2
1.96
2.72
ug/l
0.65
62
595
66
606
1.15
0.34
4.3
2.6
—
—
—
0
0
7
52
1.36
0.31
3.1
2.8
—
—
—
0
0
35
310
1.16
0.29
5.5
2.3
—
—
—
0
0
40
360
1.15
0.27
4.1
4.0
0.00
0.00
estimate
-0.00
17
130
15
180
0.82
0.25
25.7
6.1
1.39
1.12
mmol/l
0.10
15
143
5
37
1.36
0.24
1.4
1.7
—
—
—
0
0
5
37
1.36
0.24
1.0
1.2
—
1.69
—
0
7
5
41
1.23
0.22
2.2
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
2.3
—
—
—
0
0
56
526
1.10
0.19
4.5
3.9
—
—
—
0
0
30
273
1.12
0.18
1.7
1.7
1029.90
1239.21
nmol/l
0.92
23
207
15
171
0.86
0.15
8.2
7.7
—
—
—
0
0
90
870
1.08
0.15
3.2
3.4
50.05
54.57
u/l
0.23
85
805
16
177
0.89
0.11
24.1
6.0
10.61
11.62
kpa
1.02
16
171
16
177
0.89
0.11
24.2
6.0
5.10
5.03
kpa
0.08
16
170
5
43
1.17
0.10
2.2
1.9
—
—
—
0
0
6
53
1.14
0.09
5.2
2.5
864.67
1233.92
ug/l
—
6
46
6
54
1.12
0.09
1.2
3.8
—
3.54
—
0
7
6
71
0.84
0.08
2.8
3.5
89.00
720.91
u/ml
—
6
57
8
73
1.10
0.07
46.6
5.3
27.55
24.51
mmol/l
—
8
73
14
133
1.06
0.01
1.4
2.3
12.97
13.05
nmol/l
0.01
14
122
31
303
1.03
0.01
1.8
1.9
453.42
439.46
pmol/l
0.11
24
252
45
443
1.02
0.01
3.9
3.6
33.53
36.31
u/l
0.25
45
416
45
446
1.01
0.00
2.3
2.7
75.88
67.21
u/l
0.12
40
413
16
165
0.97
0.00
1.6
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
25.20
—
0
5
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
16.36
—
0
5
0
5
0.00
0.00
0.0
1.2
—
56.00
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
6
65
0.92
-0.00
5.7
1.9
1.85
5.52
ug/l
—
6
60
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
9
98
0.91
-0.00
1.6
1.9
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.3
—
69.11
—
0
9
0
6
0.00
-0.00
0.0
2.8
—
13.62
—
0
6
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_PARAPSO_RETIFORM and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 1.069 [0.8, 1.43] | 0.653 |
| Birth year | 0.993 [0.98, 1.0] | 0.156 |
During the follow-up period (1.1.1998 — 31.12.2019), 59 out of 274 females with L12_PARAPSO_RETIFORM died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_PARAPSO_RETIFORM | 0.92 [0.76, 1.11] | 0.388 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 139 out of 529 males with L12_PARAPSO_RETIFORM died.
Mortality risk
Mortality risk for people of age
years, who have L12_PARAPSO_RETIFORM.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.084% | 0.16% |
| 5 | 0.627% | 0.949% |
| 10 | 1.432% | 2.37% |
| 15 | 2.799% | 4.725% |
| 20 | 5.179% | 8.278% |
Relationships between endpoints
↥Index endpoint: L12_PARAPSO_RETIFORM – Other and unspecified parapsoriasis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data